Igor B Roninson, PhD. is the Founder and President of Senex Biotechnology. He is also the Director of the Center for Targeted Therapeutics, SmartState Endowed Chair and Professor at the University of South Carolina. In the past, Dr. Roninson served as the Director of the Cancer Center at Ordway Research Institute, Albany, New York and as a Distinguished Professor of Molecular Genetics and Head of the Division of Molecular Oncology, University of Illinois at Chicago. He is a winner of the 1994 C.P. Rhoads Award for Meritorious Achievement in Cancer Research. Dr. Roninson’s study that discovered the disease-associated pathway targeted by Senex’s drugs was recognized in 2000 by the first annual Life Extension Prize from the Regenerative Medicine Secretariat. Dr. Roninson has authored over 160 articles and book chapters and is an inventor of 41 issued US patents.
Lawrence T. Friedhoff, MD, PhD, FACP served as the CEO of Senex from 2007 -2014. He is a drug development expert who has a history of six successful drug approvals over his nearly 30 years in the pharmaceutical industry. Drugs developed by Dr. Friedhoff and his teams have cumulative revenues of over $50 billion.
Robert (Bob) Bonczek is the founding partner of Aspentree Capital, a boutique investment company and President and CFO of MedBlue Incubator. Mr Bonczek has served as the CFO and/or President at various other companies including B3Bio, C2 Regenerate and Trimeris. In addition, he serves on the board of about 10 companies. Mr. Bonczek holds a JD from UNC and an MBA from Wharton.
Richard L. Davidson, PhD. is Executive Director of the Kimmel Cancer Center and Research Professor of Microbiology, Thomas Jefferson University, Philadelphia, PA. Dr. Davidson is renowned for his studies in somatic cell genetics and mechanisms of mutagenesis and carcinogenesis.